BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19123922)

  • 1. C-Terminal membrane spanning region of human heme oxygenase-1 mediates a time-dependent complex formation with cytochrome P450 reductase.
    Huber Iii WJ; Scruggs BA; Backes WL
    Biochemistry; 2009 Jan; 48(1):190-7. PubMed ID: 19123922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein/protein interactions in the mammalian heme degradation pathway: heme oxygenase-2, cytochrome P450 reductase, and biliverdin reductase.
    Spencer AL; Bagai I; Becker DF; Zuiderweg ER; Ragsdale SW
    J Biol Chem; 2014 Oct; 289(43):29836-58. PubMed ID: 25196843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and characterization of full-length human heme oxygenase-1: the presence of intact membrane-binding region leads to increased binding affinity for NADPH cytochrome P450 reductase.
    Huber WJ; Backes WL
    Biochemistry; 2007 Oct; 46(43):12212-9. PubMed ID: 17915953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reactions of heme- and verdoheme-heme oxygenase-1 complexes with FMN-depleted NADPH-cytochrome P450 reductase. Electrons required for verdoheme oxidation can be transferred through a pathway not involving FMN.
    Higashimoto Y; Sato H; Sakamoto H; Takahashi K; Palmer G; Noguchi M
    J Biol Chem; 2006 Oct; 281(42):31659-67. PubMed ID: 16928691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of NADPH in the interaction between heme oxygenase-1 and cytochrome P450 reductase.
    Higashimoto Y; Sakamoto H; Hayashi S; Sugishima M; Fukuyama K; Palmer G; Noguchi M
    J Biol Chem; 2005 Jan; 280(1):729-37. PubMed ID: 15516695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human heme oxygenase-1 efficiently catabolizes heme in the absence of biliverdin reductase.
    Reed JR; Huber WJ; Backes WL
    Drug Metab Dispos; 2010 Nov; 38(11):2060-6. PubMed ID: 20679134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of danthron as an isoform-specific inhibitor of HEME OXYGENASE-1/cytochrome P450 reductase interaction with anti-tumor activity.
    Chou YT; Hsu FF; Hu DY; Chen YC; Hsu YH; Hsu JT; Chau LY
    J Biomed Sci; 2018 Jan; 25(1):6. PubMed ID: 29361943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of oxaporphyrin ring of CO-bound α-verdoheme complexed with heme oxygenase-1 by NADPH-cytochrome P450 reductase.
    Sato H; Higashimoto Y; Sakamoto H; Sugishima M; Shimokawa C; Harada J; Palmer G; Noguchi M
    J Inorg Biochem; 2011 Feb; 105(2):289-96. PubMed ID: 21194630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.
    Marohnic CC; Huber Iii WJ; Patrick Connick J; Reed JR; McCammon K; Panda SP; Martásek P; Backes WL; Masters BS
    Arch Biochem Biophys; 2011 Sep; 513(1):42-50. PubMed ID: 21741353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer.
    Yanatori I; Richardson DR; Toyokuni S; Kishi F
    J Biol Chem; 2017 Aug; 292(32):13205-13229. PubMed ID: 28655775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme oxygenase isoforms differ in their subcellular trafficking during hypoxia and are differentially modulated by cytochrome P450 reductase.
    Linnenbaum M; Busker M; Kraehling JR; Behrends S
    PLoS One; 2012; 7(4):e35483. PubMed ID: 22545110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of membrane-bound human heme oxygenase-1 activity using a chemically defined assay system.
    Huber WJ; Marohnic CC; Peters M; Alam J; Reed JR; Masters BS; Backes WL
    Drug Metab Dispos; 2009 Apr; 37(4):857-64. PubMed ID: 19131520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometric identification of lysine residues of heme oxygenase-1 that are involved in its interaction with NADPH-cytochrome P450 reductase.
    Higashimoto Y; Sugishima M; Sato H; Sakamoto H; Fukuyama K; Palmer G; Noguchi M
    Biochem Biophys Res Commun; 2008 Mar; 367(4):852-8. PubMed ID: 18194664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the electron transfer from an open form of NADPH-cytochrome P450 oxidoreductase to heme oxygenase.
    Sugishima M; Sato H; Higashimoto Y; Harada J; Wada K; Fukuyama K; Noguchi M
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2524-9. PubMed ID: 24550278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heme oxygenase-1 affects cytochrome P450 function through the formation of heteromeric complexes: Interactions between CYP1A2 and heme oxygenase-1.
    Connick JP; Reed JR; Cawley GF; Backes WL
    J Biol Chem; 2021; 296():100030. PubMed ID: 33148696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteromeric complex formation between human cytochrome P450 CYP1A1 and heme oxygenase-1.
    Connick JP; Reed JR; Cawley GF; Backes WL
    Biochem J; 2021 Jan; 478(2):377-388. PubMed ID: 33394027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of heme oxygenase-1 from cyanobacterium Synechocystis sp. PCC 6803 in complex with heme.
    Sugishima M; Migita CT; Zhang X; Yoshida T; Fukuyama K
    Eur J Biochem; 2004 Nov; 271(22):4517-25. PubMed ID: 15560792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoporphyrin intermediate in heme oxygenase catalysis. Oxidation of alpha-meso-phenylheme.
    Evans JP; Niemevz F; Buldain G; de Montellano PO
    J Biol Chem; 2008 Jul; 283(28):19530-9. PubMed ID: 18487208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational Equilibrium of NADPH-Cytochrome P450 Oxidoreductase Is Essential for Heme Oxygenase Reaction.
    Sugishima M; Taira J; Sagara T; Nakao R; Sato H; Noguchi M; Fukuyama K; Yamamoto K; Yasunaga T; Sakamoto H
    Antioxidants (Basel); 2020 Jul; 9(8):. PubMed ID: 32731542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.
    Pandey AV; Flück CE; Mullis PE
    Biochem Biophys Res Commun; 2010 Sep; 400(3):374-8. PubMed ID: 20732302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.